Hanyu Medical Raises ￥500 million in Extended Series D Round

(VCBeat) Mar. 15, 2021 -- Shanghai-based Hanyu Medical today announced extended that investment round by an additional 500 million yuan. The round's extension was led by YF Capital, with participation from Winfast Holding, Octagon Capital, E Fund Management, Linden Asset Group and the existing investor Highlight Capital. Bairong Capital acted as the exclusive financial adviser for this round.

Established in December 2016, Hanyu Medical is the first domestic company engaged in the research, development, production, and sales of heart valve interventional medical devices.

ValveClamp, independently developed by Hanyu Medical, is a mitral valve repair device with a global invention patent, which is used for minimally invasive treatment of mitral regurgitation. ValveClamp has passed 12 exploratory clinical trials in October 2018 and started premarket clinical trials in February 2019. It is the first self-developed minimally invasive device for mitral valve repair in China to enter premarket clinical trials and is expected to become the first domestic counterpart to be listed in China after Abbott's.

Hongyu Medical, a subsidiary of Hanyu Medical as a platform for the R&D and commercialization of animal medical devices, is the first company in the world to develop interventional medical devices for mitral regurgitation in pet dogs. With the help of the company's rich experience in clinical R&D, Hongyu Medical has developed a number of portfolios for the treatment of structural heart disease in pets. It has successively reached cooperation with pet medical teams in the United States, Italy, Japan, Spain, the United Kingdom, Israel, and other countries.

Founded in 2010, YF Capital is a leading private equity firm in China. YF Capital currently manages multiple USD and RMB funds. The company has formed deep sector expertise and industry insights in our focused sectors, including the internet, technology, healthcare, entertainment, consumer, finance and logistics.

Winfast is a fund-management & investment group founded in 2003, with a current investment scale of more than 10 billion yuan. Its business has covered the primary, primary and half, and secondary markets.